Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Psychopharmacology of COVID-19

© 2020 Published by Elsevier Inc. on behalf of Academy of Consultation-Liaison Psychiatry.

Background: With the rapid, global spread of SARS-CoV-2, hospitals have become inundated with patients suffering from COVID-19. Consultation-liaison psychiatrists are actively involved in managing these patients and should familiarize themselves with how the virus and its proposed treatments can affect psychotropic management. The only FDA approved drug to treat COVID-19 is remdesivir, and other off-label medications used include chloroquine and hydroxychloroquine, tocilizumab, lopinavir/ritonavir, favipiravir, convalescent plasma therapy, azithromycin, vitamin C, corticosteroids, interferon and colchicine

Purpose: To provide an overview of the major safety considerations relevant to clinicians who prescribe psychotropics to patients with COVID-19, both related to the illness and its proposed treatments

Methods: In this targeted review we performed structured literature searches in PubMed to identify articles describing the impacts of COVID-19 on different organ systems, the neuropsychiatric adverse effects of treatments, and any potential drug interactions with psychotropics. The articles most relevant to this manuscript were included

Results: COVID-19 impacts multiple organ systems, including gastrointestinal, renal, cardiovascular, pulmonary, immunological, and hematological systems. This may lead to pharmacokinetic changes that impact psychotropic medications and increase sensitivity to psychotropic-related adverse effects. Additionally, several proposed treatments for COVID-19 have neuropsychiatric effects and potential interactions with commonly used psychotropics

Conclusion: Clinicians should be aware of the need to adjust existing psychotropics or avoid using certain medications in some COVID-19 patients. They should also be familiar with ne... Full description

Year of Publication: 2020
Contained in: Psychosomatics (18.05.2020)
All journal articles: Search for all articles in this journal
Language: English
Contributors: Bilbul, Melanie | Author
Paparone, Patricia
Kim, Anna M
Mutalik, Shruti
Ernst, Carrie L
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
Journal Article
Review
psychopharmacology
psychotropic
side effects
ISSN: 1545-7206
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 27.06.2020
published: Print-Electronic
Citation Status Publisher
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32425246
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.psym.2020.05.006
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03629nma a2200577 c 4500
001 NLM310948657
003 DE-601
005 20200627213808.0
007 cr uuu---uuuuu
008 200519s2020 000 0 eng d
024 7 |a 10.1016/j.psym.2020.05.006  |2 doi 
028 5 2 |a pubmed20n1247.xml 
035 |a (DE-599)NLM32425246 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Bilbul, Melanie 
245 1 0 |a Psychopharmacology of COVID-19  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Revised 27.06.2020 
500 |a published: Print-Electronic 
500 |a Citation Status Publisher 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a © 2020 Published by Elsevier Inc. on behalf of Academy of Consultation-Liaison Psychiatry. 
520 |a Background: With the rapid, global spread of SARS-CoV-2, hospitals have become inundated with patients suffering from COVID-19. Consultation-liaison psychiatrists are actively involved in managing these patients and should familiarize themselves with how the virus and its proposed treatments can affect psychotropic management. The only FDA approved drug to treat COVID-19 is remdesivir, and other off-label medications used include chloroquine and hydroxychloroquine, tocilizumab, lopinavir/ritonavir, favipiravir, convalescent plasma therapy, azithromycin, vitamin C, corticosteroids, interferon and colchicine 
520 |a Purpose: To provide an overview of the major safety considerations relevant to clinicians who prescribe psychotropics to patients with COVID-19, both related to the illness and its proposed treatments 
520 |a Methods: In this targeted review we performed structured literature searches in PubMed to identify articles describing the impacts of COVID-19 on different organ systems, the neuropsychiatric adverse effects of treatments, and any potential drug interactions with psychotropics. The articles most relevant to this manuscript were included 
520 |a Results: COVID-19 impacts multiple organ systems, including gastrointestinal, renal, cardiovascular, pulmonary, immunological, and hematological systems. This may lead to pharmacokinetic changes that impact psychotropic medications and increase sensitivity to psychotropic-related adverse effects. Additionally, several proposed treatments for COVID-19 have neuropsychiatric effects and potential interactions with commonly used psychotropics 
520 |a Conclusion: Clinicians should be aware of the need to adjust existing psychotropics or avoid using certain medications in some COVID-19 patients. They should also be familiar with neuropsychiatric effects of medications being used to treat this disease. Further research is needed to identify strategies to manage psychiatric issues in this population 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
655 7 |a COVID-19  |2 gnd 
655 7 |a psychopharmacology  |2 gnd 
655 7 |a psychotropic  |2 gnd 
655 7 |a side effects  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a psychopharmacology 
689 1 2 |a psychotropic 
689 1 3 |a side effects 
689 1 |5 DE-601 
700 1 |a Paparone, Patricia 
700 1 |a Kim, Anna M 
700 1 |a Mutalik, Shruti 
700 1 |a Ernst, Carrie L 
773 0 8 |i in  |t Psychosomatics  |g  (18.05.2020)  |w (DE-601)NLM000063762  |x 1545-7206 
856 4 1 |u http://dx.doi.org/10.1016/j.psym.2020.05.006  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |j 2020  |b 18  |c 05